Clinical Trials
3 trialsNCT05132582 2026-04-20
HER2CLIMB-05
Seagen Inc.
Phase 3 Active not recruiting
NCT03975647 2026-03-30
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Seagen Inc.
Phase 3 Active not recruiting
NCT04457596 2025-10-29
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting